AIGH Capital Management LLC Makes New Investment in KALA BIO, Inc. (NASDAQ:KALA)

AIGH Capital Management LLC purchased a new stake in KALA BIO, Inc. (NASDAQ:KALA) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 121,302 shares of the company’s stock, valued at approximately $842,000.

KALA BIO Stock Performance

NASDAQ KALA opened at $6.05 on Friday. The firm has a market capitalization of $36.85 million, a P/E ratio of -0.49 and a beta of -2.19. The company has a current ratio of 2.15, a quick ratio of 2.15 and a debt-to-equity ratio of 3.18. The firm’s fifty day moving average price is $7.70 and its two-hundred day moving average price is $6.81. KALA BIO, Inc. has a 1 year low of $4.21 and a 1 year high of $11.20.

Insider Buying and Selling at KALA BIO

In related news, CEO Mark T. Iwicki sold 5,779 shares of KALA BIO stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.63, for a total transaction of $44,093.77. Following the completion of the sale, the chief executive officer now directly owns 280,076 shares of the company’s stock, valued at approximately $2,136,979.88. This trade represents a 2.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Bros. Advisors Lp Baker acquired 310,559 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was purchased at an average cost of $6.44 per share, for a total transaction of $1,999,999.96. Following the completion of the acquisition, the insider now owns 1,083,398 shares in the company, valued at approximately $6,977,083.12. This represents a 40.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 9,506 shares of company stock valued at $72,531 in the last quarter. 8.32% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of KALA BIO in a research note on Thursday, February 13th.

KALA BIO Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.